ARTICLES
Sleep-Related Problems Among Children and Adolescents With Anxiety Disorders

https://doi.org/10.1097/01.chi.0000242233.06011.8eGet rights and content

ABSTRACT

Objective

The present study examined sleep-related problems (SRPs) among a large sample (n = 128) of youth with anxiety disorders (i.e., generalized, separation, and social). The frequency of eight specific SRPs was examined in relation to age, gender, type of anxiety disorder, anxiety severity, and functional impairment. The impact of pharmacological treatment (fluvoxamine versus pill placebo) in reducing SRPs also was examined.

Method

As part of a large, double-blind, randomized, controlled trial (Research Units on Pediatric Psychopharmacology Anxiety Study Group), clinician and parent reports of SRPs were examined among children and adolescents, ages 6 to 17 years, before and after treatment.

Results

Eighty-eight percent of youth experienced at least one SRP, and a majority (55%) experienced three or more. Total SRPs were positively associated with anxiety severity and interference in family functioning. Significantly greater reductions in SRPs were found among children treated with fluvoxamine compared with placebo.

Conclusions

These findings indicate that SRPs are commonly associated with childhood anxiety disorders and suggest a need for the assessment of and attention to these problems in research and clinical settings.

Section snippets

Participants

Participants were 128 children, 6 to 17 years of age (mean, 10.8 years), who met DSM-IV criteria for GAD, SAD, and/or SOC on the basis of child and parent Schedule for Affective Disorders and Schizophrenia for School-Aged Children (Kaufman et al., 1997) interviews with a trained clinician (see Research Units on Pediatric Psychopharmacology Anxiety Study Group, 2001). All children were enrolled in a double-blind, placebo-controlled, clinical trial of FLV for youth with anxiety disorders (i.e.,

Gender, Age, and Anxiety Disorder

Frequencies of the eight sleep items are presented in Tables 2 and 3 for the total sample and by gender, age group, and diagnosis (GAD, SAD, and SOC). Eighty-eight percent of the total sample reported at least one SRP; 55% reported three or more SRPs. The most common SRPs were insomnia, nightmares, and refusal/reluctance to sleep alone.

Prevalence of SRPs Among Anxious Youth

Eighty-eight percent of anxious youth experienced at least one SRP, and more than half experienced three or more. The most common SRPs were insomnia, nightmares, and reluctance/refusal to sleep alone. Rates of insomnia found in the present study are consistent with data indicating insomnia to be present among 60% to 70% of adults with anxiety disorders (Ohayon, 1997, Uhde, 2000). Although there were no gender or age differences in total number of SRPs, nightmares were significantly more common

REFERENCES (31)

  • P Sandor et al.

    Sleep patterns in depression and anxiety: theory and pharmacological effects

    J Psychosom Res

    (1994)
  • SL Warren et al.

    Maternal panic disorder: infant temperament, neurophysiology, and parenting behaviors

    J Am Acad Child Adolesc Psychiatry

    (2003)
  • TM Achenbach et al.

    Manual for the Child Behavior Checklist

    (1991)
  • MR Dadds et al.

    Family process and child anxiety and aggression: an observational analysis

    J Abnorm Child Psychol

    (1996)
  • RE Dahl

    The regulation of sleep and arousal: development and psychopathology

    Dev Psychopathol

    (1996)
  • Cited by (274)

    • Sleep-Related Problems and Pediatric Anxiety Disorders

      2024, Psychiatric Clinics of North America
    View all citing articles on Scopus

    Preparation of this paper was supported by NIMH grant K23-MH63427-02 awarded to Dr. Ginsburg.

    The authors wish to acknowledge the Research Units on Pediatric Psychopharmacology Anxiety Group (RUPP) sites that supported the data collection for this study: Mark A. Riddle, M.D., John T. Walkup, M.D., and Michael J. Labellarte, M.D., Johns Hopkins University; Daniel S. Pine, M.D., Laurence Greenhill, M.D., Rachel Klein, Ph.D., and Michael Sweeney, Ph.D., Columbia University and New York State Psychiatric Institute; Howard Abikoff, Ph.D., Sabine Hack, M.D., and Brian Klee, M.D., New York University; James McCracken, M.D., Lindsey Bergman, Ph.D., and John Piacentini, Ph.D., University of California, Los Angeles; John March, M.D., M.P.H., and Scott Compton, Ph.D., Duke University; and Ben Vitiello, M.D., National Institute of Mental Health.

    Disclosure: The authors have no financial relationships to disclose.

    1

    Dr. Alfano is with the Department of Psychiatry, Children's National Medical Center, Washington, DC; Drs. Ginsburg and Kingery are with the Department of Psychiatry and Behavioral Sciences, Division of Child and Adolescent Psychiatry, Johns Hopkins University School of Medicine, Baltimore.

    View full text